Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Genzyme Reports Additional Data From Phase III CARE-MS II Trial

RELATED NEWS
Trade SNY now with 

Genzyme, a Sanofi company (SNY: Quote), on Tuesday reported additional data from the Phase III CARE-MS II trial.

Accumulation of disability was significantly slowed in patients with multiple sclerosis who were treated with alemtuzumab versus Rebif, as measured by the Expanded Disability Status Scale, a standard assessment of physical disability progression.

In addition, significant improvement in disability scores was observed in some patients treated with alemtuzumab from baseline and compared to patients treated with Rebif, suggesting a reversal of disability in these patients. In the trial, patients with pre-existing disability treated with alemtuzumab were more than twice as likely to experience a sustained reduction in disability than patients given Rebif.

Genzyme is developing alemtuzumab in multiple sclerosis in collaboration with Bayer HealthCare.

CARE-MS II was a randomized Phase III clinical trial comparing the investigational drug alemtuzumab to Rebif in patients with relapsing-remitting multiple sclerosis who had relapsed while on prior therapy. The company announced in November that results for the co-primary endpoints of the trial were highly statistically significant. Additional new data from the CARE-MS II study suggest that alemtuzumab provided significant improvement over Rebif across a number of imaging endpoints, consistent with the effects observed in the clinical endpoints. The company said it is on track to file for U.S. and EU approval of alemtuzumab in relapsing multiple sclerosis in the second quarter of 2012.

Register
To receive FREE breaking news email alerts for Sanofi and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The Eurozone private sector growth eased more-than-expected in August as weak manufacturing performance hurt Germany's expansion, while the French private sector activity stagnated. The Eurozone composite output index fell to 52.8 in August from 53.8 in July, flash data from Markit Economics showed Thursday. The indicator was expected to fall marginally to 53.4. In the worst blow Israel inflicted on Hamas since Operation Protective Edge began on July 8, three senior Hamas military commanders were killed in overnight air strikes on Gaza. The Islamist movement that controls the Gaza Strip said Mohammed Abu Shammala, Raed al-Attar and Mohammed Barhoum were killed in a bombing of a house in the southern town of Rafah. They were the Hamas masterminds of smuggl Computer and printer maker Hewlett-Packard Co. (HPQ) said Wednesday after the markets closed that its third quarter profit fell 29% from last year, hurt mainly by higher restructuring charges even as revenue grew 1%. The company's quarterly earnings per share, excluding items, came in line with analysts' expectations, but its quarterly revenue beat analysts' forecast.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.